Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Panel Backs Xeljanz for Ulcerative Colitis
May 1, 2018
- MHLW Proposes Discussing Proper Use of High-Cost Biologics in Preparation for Revision of RA Measures
April 27, 2018
- Imfinzi Sails through MHLW Panel, Now in Line for Stage III NSCLC Nod
April 26, 2018
- MHLW Starts Discussing Blood Law Amendment Focusing on Use of Blood-Derived iPS Cells, New Entrants into Blood Collection
April 26, 2018
- Patients Won’t Benefit without Change in Mindset among Researchers: AMED President
April 25, 2018
- ICER-Based Price Tweaks “Scientifically Difficult,” Impact on Cost Cuts Limited: Prof.
April 25, 2018
- Tap Data from “Specified Clinical Research” for Early Trial, Conditional Approval: JPMA Official
April 24, 2018
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR
April 20, 2018
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official
April 19, 2018
- Generic Industry Asks for Govt Support for Continuous Manufacturing to Boost Int’l Competitiveness: Public-Private Confab
April 17, 2018
- No Company Supports New Price Maintenance Premium Scheme: FPMAJ Survey
April 17, 2018
- Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
April 17, 2018
- Generic Drug Makers Required to Improve Package Inserts by Adding Information from Clinical Studies: MHLW Notification
April 17, 2018
- Xeljanz’s Ulcerative Colitis Use Up for MHLW Panel Review on April 27
April 16, 2018
- MHLW to Draft GL on Detailing Activities by Drug Reps as Early as Summer
April 13, 2018
- MHLW Compiles Drug Reuse Guide to Reduce Leftover Drug Solutions
April 13, 2018
- AZ’s PD-L1 Inhibitor Durvalumab Up for MHLW Panel Review on April 25
April 13, 2018
- MHLW to Issue Optimal Use Guidelines for Dupixent, Tecentriq
April 12, 2018
- MHLW Panel Starts Discussions on PMD Law Amendment; Will First Verify Results of Previous Amendment
April 12, 2018
- Chuikyo Holds 1st Listing Discussions since Overhaul, US Reference Prices Show Marked Declines after Rule Change
April 12, 2018
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…